These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 15624287)

  • 1. Pharmacokinetics of immunosuppressants: a perspective on ethnic differences.
    Dirks NL; Huth B; Yates CR; Meibohm B
    Int J Clin Pharmacol Ther; 2004 Dec; 42(12):701-18. PubMed ID: 15624287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes in ethnic minority renal transplant recipients receiving everolimus versus mycophenolate: comparative risk assessment results from a pooled analysis.
    Melancon K; Mulgaonkar SP; Delcoro C; Wiland A; McCague K; Shihab FS
    Transplantation; 2013 Dec; 96(12):1073-81. PubMed ID: 24345868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction?
    Lam S; Partovi N; Ting LS; Ensom MH
    Ann Pharmacother; 2008 Jul; 42(7):1037-47. PubMed ID: 18594053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression.
    Mehra MR; Uber PA; Scott RL; Park MH
    Transplantation; 2002 Dec; 74(11):1568-73. PubMed ID: 12490790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I.
    Monchaud C; Marquet P
    Clin Pharmacokinet; 2009; 48(7):419-62. PubMed ID: 19691367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.
    Haufroid V; Mourad M; Van Kerckhove V; Wawrzyniak J; De Meyer M; Eddour DC; Malaise J; Lison D; Squifflet JP; Wallemacq P
    Pharmacogenetics; 2004 Mar; 14(3):147-54. PubMed ID: 15167702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients.
    Renders L; Frisman M; Ufer M; Mosyagin I; Haenisch S; Ott U; Caliebe A; Dechant M; Braun F; Kunzendorf U; Cascorbi I
    Clin Pharmacol Ther; 2007 Feb; 81(2):228-34. PubMed ID: 17192769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil.
    McCrea JB; Macha S; Adedoyin A; Marshall W; Menzel K; Cho CR; Liu F; Zhao T; Levine V; Kraft WK; Yoon E; Panebianco D; Stoch SA; Iwamoto M
    J Clin Pharmacol; 2019 Oct; 59(10):1331-1339. PubMed ID: 30990905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics and immunosuppressive drugs in solid organ transplantation.
    van Gelder T; van Schaik RH; Hesselink DA
    Nat Rev Nephrol; 2014 Dec; 10(12):725-31. PubMed ID: 25247332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
    Op den Buijsch RA; Christiaans MH; Stolk LM; de Vries JE; Cheung CY; Undre NA; van Hooff JP; van Dieijen-Visser MP; Bekers O
    Fundam Clin Pharmacol; 2007 Aug; 21(4):427-35. PubMed ID: 17635182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations.
    del Mar Fernández De Gatta M; Santos-Buelga D; Domínguez-Gil A; García MJ
    Clin Pharmacokinet; 2002; 41(2):115-35. PubMed ID: 11888332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients?
    Li P; Shuker N; Hesselink DA; van Schaik RH; Zhang X; van Gelder T
    Transpl Int; 2014 Oct; 27(10):994-1004. PubMed ID: 24963914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive drugs in paediatric liver transplantation.
    van Mourik ID; Kelly DA
    Paediatr Drugs; 2001; 3(1):43-60. PubMed ID: 11220404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of mycophenolate mofetil on long-term outcomes in African american renal transplant recipients.
    Meier-Kriesche HU; Ojo AO; Leichtman AB; Punch JD; Hanson JA; Cibrik DM; Kaplan B
    J Am Soc Nephrol; 2000 Dec; 11(12):2366-2370. PubMed ID: 11095660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.
    Ahsan N; Johnson C; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
    Transplantation; 2001 Jul; 72(2):245-50. PubMed ID: 11477347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
    Kovarik JM; Curtis JJ; Hricik DE; Pescovitz MD; Scantlebury V; Vasquez A
    Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.
    Hu YF; Qiu W; Liu ZQ; Zhu LJ; Liu ZQ; Tu JH; Wang D; Li Z; He J; Zhong GP; Zhou G; Zhou HH
    Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1093-8. PubMed ID: 17042920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.